"Linezolid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract.
| Descriptor ID |
D000069349
|
| MeSH Number(s) |
D02.065.064.463 D02.241.081.018.110.525 D03.383.129.462.600.550
|
| Concept/Terms |
Linezolid- Linezolid
- N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
- Linezolide
U 100766- U 100766
- 100766, U
- PNU-100766
- PNU 100766
- PNU100766
- U-100766
- U100766
|
Below are MeSH descriptors whose meaning is more general than "Linezolid".
Below are MeSH descriptors whose meaning is more specific than "Linezolid".
This graph shows the total number of publications written about "Linezolid" by people in this website by year, and whether "Linezolid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 6 | 6 |
| 2005 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2020 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Linezolid" by people in Profiles.
-
Pathogenic Role and Antibiotic Resistance of Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Causing Severe Community-Acquired Pneumonia in Vietnamese Children. Adv Respir Med. 2023 Mar 30; 91(2):135-145.
-
Detection of Genes Encoding Microbial Surface Component Recognizing Adhesive Matrix Molecules in Methicillin-Resistant Staphylococcus aureus Isolated from Pyoderma Patients. Genes (Basel). 2023 03 24; 14(4).
-
New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents. J Pediatric Infect Dis Soc. 2022 Oct 31; 11(Supplement_3):S101-S109.
-
Antimicrobial susceptibility of Staphylococcus species isolated from prosthetic joints with a focus on fluoroquinolone-resistance mechanisms. Diagn Microbiol Infect Dis. 2021 Jan; 99(1):115173.
-
Retrospective Analysis of Antimicrobial Susceptibility Profiles of Nocardia Species from a Tertiary Hospital and Reference Laboratory, 2011 to 2017. Antimicrob Agents Chemother. 2020 02 21; 64(3).
-
In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients. J Antibiot (Tokyo). 2014 Jul; 67(7):505-9.
-
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 01; 59(1):51-61.
-
Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients. Int J Antimicrob Agents. 2013 Jun; 41(6):516-20.
-
Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children. Pediatr Infect Dis J. 2011 Sep; 30(9):804-6.
-
Clinical outcomes of linezolid vs vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis. J Intensive Care Med. 2011 Nov-Dec; 26(6):385-91.